Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

  • Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients
  • The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients
  • In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder
  • MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an emerging biotechnology and digital company dedicated to efficiently developing first- and second-generation novel therapeutics to treat PTSD, addiction, and other mental health disorders, has achieved a significant milestone for its drug development pipeline.

The Denver-based company recently filed a technology patent application that will cover as well as allow for the creation of formulations that use nanoemulsion technology to improve, stabilize, increase bioavailability, and make repeatable properties of ingredients from traditional medicines. The formulations to be covered by the patent are Generally Recognized as Safe (“GRAS”) – an FDA certification that designates that a food substance or chemical additive is considered safe by experts (https://ibn.fm/WYhxm).

An advanced drug delivery system, nanoemulsion has the potential of improving the bioavailability of multiple active pharmaceutical ingredients (“APIs”). In addition, it offers enhanced stability, fast digestibility, controlled release, and protection against degradation (https://ibn.fm/wLgMH). Specifically, Mydecine is targeting the enhanced bioavailability and controlled release capabilities of the nanoemulsion technology.

The system’s controlled-release capability, for example, will be instrumental in the company’s active drug development by aiding in micro-dosing and customizing dosages. Similarly, Mydecine’s GRAS-pending formulations will provide an opportunity to enhance the bioavailability of natural compounds found in traditional medicine, including reishi and cordyceps, allowing them to be added to a growing variety of consumer products to achieve improved benefits.

“By fine-tuning our ingredients and extraction processes, we are able to deliver these valuable properties more accurately and effectively to consumers,” said Rob Roscow, the Chief Science Officer at MYCOF.

On his part, CEO Josh Bartch noted that the patent application had introduced an additional wall of IP protection that covers vital technologically innovative properties of compounds that can empower multiple over-the-counter (“OTC”) supplements and consumer products.

“The compatibility of these formulas as patent-protected ingredients has Mydecine excited to develop a wide variety of licensing opportunities,” Josh added. “As we continue to produce new methods to traditional medicinal roots, it is critical that we apply layerable patented technology to our discovery process in order to enhance the use of extracts and take advantage of increasing demand for these valuable compounds in today’s health treatments.”

In addition to continuing with the development of compounds inspired by traditional ingredients but empowered by modern nanoemulsion technology to enhance bioavailability and optimize delivery to users, Mydecine also intends to use the same technology in OTC consumer products to improve usability and accessibility.

Notably, the recent technology patent filing follows on the heels of a September 22 announcement that Mydecine filed its final patent application with the United States Patent and Trademark Office (“USPTO”) and the World Intellectual Property Organization (“WIPO”) for MYCO-003, one of its lead drug candidates. MYCO-003 is a psilocybin formulation developed to offer enhanced treatment of post-traumatic stress disorder (“PTSD”) and anxiety (https://ibn.fm/Uujxl).

Committed to finding answers to mental health challenges, Mydecine has submitted multiple pending patents for novel innovation in first- and second-generation drugs and compounds. Through its latest technology patent filing, coupled with the September final patent application, the company is steadily strengthening its intellectual property (“IP”) portfolio as it seeks to reimagine mental health and addiction treatment with safer, more effective solutions.

For more information, visit the company’s website at www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050